VIP syndrome in surgical oncology: ethical and clinical challenges in resource-limited settings [0.03%]
外科肿瘤学中的 VIP 综合征：资源有限条件下的伦理和临床挑战
Mukurdipi Ray,Hema Siri Kottu
Mukurdipi Ray
Radiomics for predicting sensitivity to neoadjuvant chemotherapy in osteosarcoma: current status and advances [0.03%]
放射组学在预测骨肉瘤新辅助化疗敏感性中的应用：现状与进展
Panhong Zhang,Weitao Yao,Zhehuang Li et al.
Panhong Zhang et al.
Osteosarcoma is the most common primary malignant bone tumor, accounting for approximately 20% of all primary malignant bone tumors, and predominantly affects adolescents. The current standard treatment involves a multimodal approach combin...
Global trends of esophageal cancer among individuals over 60 years: an epidemiological analysis from 1990 to 2050 based on the global burden of disease study 1990-2021 [0.03%]
基于1990年至2021年全球疾病负担研究的食管癌流行病学分析（60岁以上人群1990至2050年全球趋势）
Simiao Lu,Kexun Li,Kangning Wang et al.
Simiao Lu et al.
Objective: Esophageal cancer (EC) ranks as the sixth leading cause of cancer-related deaths globally, with over 500,000 new cases annually. Understanding trends in individuals over 60 is critical for enhancing treatment a...
eIF3b-driven autophagy and Wnt/β-catenin crosstalk: a novel regulatory axis in adriamycin resistance of breast cancer [0.03%]
乳腺癌阿霉素耐药中的eIF3b驱动的自噬和Wnt/β-catenin交叉 talk：新的调控轴心
Yanhui Li,Shurao Chen,Zihui Zhao et al.
Yanhui Li et al.
Adriamycin (ADM) resistance remains a major clinical obstacle in breast cancer chemotherapy, driven by complex mechanisms including enhanced drug efflux, apoptosis inhibition, and protective autophagy. This review explores a novel regulator...
Lung cancer associated with cystic airspaces: current progress and future perspectives [0.03%]
与含气囊腔相关的肺癌：现状和未来展望
Jiarui Wang,Jie Dai
Jiarui Wang
Lung cancer associated with cystic airspaces (LCCAs) is a distinct subtype of lung cancer defined by its unique radiological characteristics. It is increasing in prevalence but is often misdiagnosed. The constantly emerging radiological cla...
Tyrosine-kinase inhibitors for lung or breast cancer and drug-drug interactions: a clinical guide [0.03%]
肺癌和乳腺癌酪氨酸激酶抑制剂与药物相互作用的临床指南
Fiorenza Santamaria,Michela Roberto,Giulia Maltese et al.
Fiorenza Santamaria et al.
Introduction: In the last two decades, tyrosine-kinase inhibitors (TKIs) have dramatically changed the prognosis of lung and breast cancers, with significant benefits in the metastatic setting and, more recently, in the a...
A comprehensive framework for the management of hereditary breast cancers: guiding light in precision medicine [0.03%]
遗传性乳腺癌综合管理框架——精准医疗的灯塔指引
Samar Ekram,Mariam M Al Eissa
Samar Ekram
Background: The landscape of oncology varies across countries and regions, and in consanguineous populations such as Saudi Arabia, the clinical management of hereditary cancers poses a distinct challenge. Hereditary breas...
Ahmed Yakdhan Saleh,Abdulkareem Shareef,Ashok Kumar Bishoyi et al.
Ahmed Yakdhan Saleh et al.
Exercise is increasingly recognized as a safe and effective adjunct therapy across the cancer care continuum, offering improvements in physiological function, psychological wellbeing, and treatment outcomes. However, conventional one-size-f...
Patterns of immune cell infiltration and oxidative stress in cervical cancer [0.03%]
宫颈癌免疫细胞浸润及氧化应激规律
Andrea Mlambo,Shuyue Su,Qhaweni Dhlamini et al.
Andrea Mlambo et al.
Cervical cancer (CeCa) remains a significant global health burden, with complex interactions between oxidative stress and immune response playing critical roles in its pathogenesis and progression. This review synthesizes current knowledge ...
The role of everolimus in malignant bone tumor therapy: Molecular mechanisms, preclinical evidence, and advances in clinical applications [0.03%]
Everolimus在恶性骨肿瘤治疗中的作用：分子机制、临床前证据及临床应用进展
Youshu Zhang,Yao Dong,Yao Zhang et al.
Youshu Zhang et al.
Malignant bone tumors, particularly osteosarcoma, pose significant therapeutic challenges due to genomic heterogeneity, chemoresistance, and stagnant survival rates. The PI3K/AKT/mTOR pathway emerges as a central driver of tumor progression...